2025
Histopathologic Progression of Autoimmune Atrophic Gastritis: A Retrospective Review of 180 Specimens From 32 Patients.
Wang X, Jiao J, Huh W, Zhang X. Histopathologic Progression of Autoimmune Atrophic Gastritis: A Retrospective Review of 180 Specimens From 32 Patients. Archives Of Pathology & Laboratory Medicine 2025 PMID: 40509896, DOI: 10.5858/arpa.2025-0030-oa.Peer-Reviewed Original ResearchAutoimmune atrophic gastritisFollow-up biopsiesNeuroendocrine tumorsFollow-upEndoscopic excisionEnterochromaffin-like cell hyperplasiaDevelopment of neuroendocrine tumorsLong-term follow-upKi-67 indexMinimal to mild inflammationImmune-mediated inflammationPathological progressionAverage follow-upEndoscopic surveillance intervalRetrospective reviewSurveillance intervalsKi-67Cell hyperplasiaGastric adenocarcinomaNo significant changesHistological featuresAntibody statusAtrophic gastritisClinical dataIntestinal metaplasia
2022
Ki‐67 index assessment on FNA specimens of gastrointestinal stromal tumor: Correlation with mitotic rate and potential predictive value for risk stratification
Wang X, Abi‐Raad R, Tang H, Cai G. Ki‐67 index assessment on FNA specimens of gastrointestinal stromal tumor: Correlation with mitotic rate and potential predictive value for risk stratification. Cancer Cytopathology 2022, 130: 974-982. PMID: 35876606, DOI: 10.1002/cncy.22630.Peer-Reviewed Original ResearchConceptsGastrointestinal stromal tumorsKi-67 indexHigh mitotic rateLow mitotic rateCell block sectionsMitotic rateMitotic countRisk stratificationStromal tumorsSurgical specimensRisk of GISTCytology specimensMean Ki-67 indexPotential predictive valueBlock sectionsFine-needle aspiration specimensKi-67 immunostainLMR groupSurgical resectionDistal esophagusTumor sizeSpindle cellsGIST casesFNA specimensPredictive value
2021
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020
Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Network Open 2021, 4: e2131744. PMID: 34705010, PMCID: PMC8552059, DOI: 10.1001/jamanetworkopen.2021.31744.Peer-Reviewed Original ResearchConceptsNeuroendocrine neoplasmsClinical trialsNational Cancer Institute Clinical TrialsEU Clinical Trials RegisterCoprimary end pointsObjective response rateProgression-free survivalClinical Trials RegisterKi-67 indexAllied Health LiteratureQuality improvement studyPhase IISpecific disease populationsWeb of ScienceDrug licensureTrials RegisterCochrane DatabaseTumor differentiationNovel agentsDisease populationInclusion criteriaMAIN OUTCOMECumulative IndexEnrollment periodResponse rate
2020
26. GENETIC CHARACTERIZATION OF SELLAR METASTASIS FROM PRIMARY BRONCHIAL CARCINOID TUMOR OF NEUROENDOCRINE PATHOLOGY
Hong C, McGuone D, Erson-Omay E, Omay S. 26. GENETIC CHARACTERIZATION OF SELLAR METASTASIS FROM PRIMARY BRONCHIAL CARCINOID TUMOR OF NEUROENDOCRINE PATHOLOGY. Neuro-Oncology Advances 2020, 2: ii4-ii5. PMCID: PMC7401391, DOI: 10.1093/noajnl/vdaa073.016.Peer-Reviewed Original ResearchSellar metastasisCarcinoid tumorsSystemic tumorsNeuroendocrine tumorsPrimary tumorNeuroendocrine originSellar regionPituitary glandMultiple primary lung cancersSubsequent brain MRIPrimary lung cancerBronchial carcinoid tumorsLung carcinoid tumorYear old femaleKi-67 indexGenetic alterationsEndoscopic endonasal approachWhole-exome sequencingPituitary adenoma progressionFinal pathologyPituitary involvementPositive immunohistochemistryEndocrine dysfunctionHistopathological correlatesRare lesionsTumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition
Ghanim B, Rosenmayr A, Stockhammer P, Vogl M, Celik A, Bas A, Kurul IC, Akyurek N, Varga A, Plönes T, Bankfalvi A, Hager T, Schuler M, Hackner K, Errhalt P, Scheed A, Seebacher G, Hegedus B, Stubenberger E, Aigner C. Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition. Scientific Reports 2020, 10: 5784. PMID: 32238865, PMCID: PMC7113285, DOI: 10.1038/s41598-020-62813-2.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitionC-reactive proteinMalignant pleural effusionKi-67 indexPD-L1Overall survivalPleural effusionPrognostic powerPD-L1 tumor proportion scoreNegative PD-L1 statusPD-L1 positive tumorsLonger median OSMedian overall survivalPD-L1 expressionPD-L1 statusTumor proportion scoreFurther prospective validationVariety of malignanciesICI therapyMedian OSSignificant prognosticatorShorter OSIndependent prognosticatorPrognostic roleDismal prognosis
2019
Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas.
Youngblood MW, Duran D, Montejo JD, Li C, Omay SB, Özduman K, Sheth AH, Zhao AY, Tyrtova E, Miyagishima DF, Fomchenko EI, Hong CS, Clark VE, Riche M, Peyre M, Boetto J, Sohrabi S, Koljaka S, Baranoski JF, Knight J, Zhu H, Pamir MN, Avşar T, Kilic T, Schramm J, Timmer M, Goldbrunner R, Gong Y, Bayri Y, Amankulor N, Hamilton RL, Bilguvar K, Tikhonova I, Tomak PR, Huttner A, Simon M, Krischek B, Kalamarides M, Erson-Omay EZ, Moliterno J, Günel M. Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. Journal Of Neurosurgery 2019, 133: 1345-1354. PMID: 31653806, DOI: 10.3171/2019.8.jns191266.Peer-Reviewed Original ResearchClinical featuresGenomic subgroupsExact testAnterior skull base regionElevated Ki-67 indexLarge peritumoral brain edemaPeritumoral brain edemaKi-67 indexModerate predictive valueFisher's exact testRelevant clinical informationMicrocystic featuresNF2 meningiomasInvasive sampling proceduresMale patientsBrain edemaFemale sexTumor locationPatient variablesDiscovery cohortSkull base regionMidline locationPatient featuresClinical informationPredictive valueProapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma
Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, Xu ML. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Human Pathology 2019, 93: 54-64. PMID: 31425695, PMCID: PMC7038910, DOI: 10.1016/j.humpath.2019.08.008.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaCell lymphomaAnn Arbor stage IIINovel independent prognostic factorAggressive B-cell lymphomasHigh Bim expressionAverage patient ageBim expressionIndependent prognostic factorLarge academic medical centerKi-67 indexNovel prognostic markerB-cell lymphomaAcademic medical centerCyclin D1 overexpressionHuman mantle cell lymphomaMCL cohortMIPI scoreProgressive diseaseComplete responseOverall survivalPatient agePrognostic factorsTumor cell survivalFemale ratioGrading Pancreatic Neuroendocrine Tumors by Ki-67 Index Evaluated on Fine-Needle Aspiration Cell Block Material
Abi-Raad R, Lavik JP, Barbieri AL, Zhang X, Adeniran AJ, Cai G. Grading Pancreatic Neuroendocrine Tumors by Ki-67 Index Evaluated on Fine-Needle Aspiration Cell Block Material. American Journal Of Clinical Pathology 2019, 153: 74-81. PMID: 31415691, DOI: 10.1093/ajcp/aqz110.Peer-Reviewed Original Research
2018
Widespread somatic loss of heterozygosity as a possible marker of disease aggressiveness in metastatic well differentiated pancreatic neuroendocrine tumors.
Akala O, Shah R, Untch B, Kelly V, Chou J, Ladanyi M, Berger M, Klimstra D, Reidy D, Raj N. Widespread somatic loss of heterozygosity as a possible marker of disease aggressiveness in metastatic well differentiated pancreatic neuroendocrine tumors. Journal Of Clinical Oncology 2018, 36: 275-275. DOI: 10.1200/jco.2018.36.4_suppl.275.Peer-Reviewed Original ResearchLoss of heterozygositySomatic loss of heterozygosityNext-generation sequencingPancreatic neuroendocrine tumorsAltered tumorsWild typeNeuroendocrine tumorsOverall survivalWT tumorsCancer-related genesMarkers of disease aggressivenessGenome-wideClinically heterogeneous tumorsHigh grade pathologySequencing platformsInferior overall survivalAggressive pathological featuresKi-67 indexNGS platformChromosome 1Allele-specificSomatic lossMEN1 alterationsGenetic alterationsGrade pathology
2017
Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms
Sigel C, Guo H, Sigel K, Zhang M, Rekhtman N, Lin O, Klimstra D, Jungbluth A, Tang L. Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms. Cancer Cytopathology 2017, 125: 188-196. PMID: 28094897, PMCID: PMC5352475, DOI: 10.1002/cncy.21817.Peer-Reviewed Original ResearchConceptsConcurrent core needle biopsyMetastatic pancreatic neuroendocrine neoplasmsCore needle biopsyPancreatic neuroendocrine neoplasmsKi-67 indexNeedle biopsyNeuroendocrine neoplasmsKi-67Cell blocksCytological differentiationFine-needle aspirationKi-67 assessmentPredictive of survivalPredictors of outcomeStage-adjusted analysisGrading of pancreatic neuroendocrine neoplasmsMedian survivalCytological gradeNeuroendocrine tumorsCytology specimensCytologic smearsPredicting PrognosisCytological assessmentGrade 3Well-differentiated
2014
Gastroenteropancreatic high‐grade neuroendocrine carcinoma
Sorbye H, Strosberg J, Baudin E, Klimstra D, Yao J. Gastroenteropancreatic high‐grade neuroendocrine carcinoma. Cancer 2014, 120: 2814-2823. PMID: 24771552, DOI: 10.1002/cncr.28721.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyNeuroendocrine carcinomaGEP-NECKi-67High-grade neuroendocrine carcinomaKi-67 proliferation indexCell neuroendocrine carcinomaSmall cell carcinomaGastroenteropancreatic (GEPHigh-grade tumorsKi-67 indexProliferation rateLong-term survivalIntermediate-gradeLocalized diseaseNeuroendocrine neoplasmsPrognostic stratificationCell carcinomaProliferation indexTreatment optionsOptimal treatmentLow-gradeTumorChemotherapyPatients
2005
Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis
Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Modern Pathology 2005, 18: 1417-1423. PMID: 15920538, DOI: 10.1038/modpathol.3800449.Peer-Reviewed Original ResearchConceptsConventional hepatocellular carcinomaFibrolamellar carcinomaHepatocellular carcinomaClinicopathologic featuresOverall survivalTumor sizeMean Ki-67 indexAbsence of cirrhosisDistinct clinicopathologic featuresKi-67 indexMetastatic diseaseLymph nodesOverall mortalityDistant metastasisNonmetastatic casesPathologic featuresAggressive neoplasmNoncirrhotic liverCirrhotic liverCirrhosisKi-67Better outcomesCarcinomaProliferative activityYoung individuals
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply